Latest Breaking News On - ஒன்றுபட்டது கிஂக்டந் - Page 2 : comparemela.com

(1) Regulatory News: Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, is pleased to announce that the Medicines Healthcare products Regulatory Agency (MHRA) has today granted marketing authorisation for Sibnayal (ADV7103) in the UK, for the treatment of distal renal tubular acidosis (dRTA). With this authorization, and following the recent approval by the European Commission to market Sibnayal for the treatment of dRTA in the European Union, Advicenne is now able to bring to market in the EU and the UK the first and only label-approved drug for the treatment of dRTA in adults, adolescents and children aged one year and older. Advicenne now has the opportunity to make a significant difference to patients suffering from dRTA, classified as an orphan condition in Europe.

United-kingdom
United-states
Paris
France-general
France
Ashley-tapp
Mary-jane-elliott
Davide-salvi
Advicenne-euronext
David-solomon
Didier-laurens
French-financial-markets-authority-autorit